Diffuse duodenal nodular lymphoid hyperplasia: a large cohort of patients etiologically related to Helicobacter pyloriinfection

Table 1 The clinical profile of 40 patients with diffuse duodenal nodular hyperplasia.

Group	All patients	H pylori eradicated group	H pylori persistent group	P value (Eradicated vs. Non-eradicated)
Number of patients	40	26	14
Age (years ± 1SD)	35.6 ± 14.6	33.6 ± 11.6	37.6 ± 15.6	0.29c
Sex (Male: Female)	23:17	15:11	8:6	0.64a
Symptoms (Number of patients)
Pain	40	26	14	1.00a
Vomiting	38	24	14	0.41a
Weight loss	35	23	12	0.77a
Diarrhoea	6	4	2	0.65a
Constipation	4	1	3	0.11a
Hemoglobin (g/dl)	9.5 ± 2.2	8.9 ± 3.2	9.7 ± 1.2	0.33c
Serum albumin (g/dl)	3.2 ± 1.1	3.4 ± 1.1	2.9 ± 1.4	0.39c
Immunoglobulins (Number of patients)
Normal	26	18	8	0.14a
Elevated IgG	6	4	2	0.65a
Elevated IgM	5	4	1	0.41a
Elevated IgA	3	0	3	0.03a
Gastroscopic findings (number of patients)
No abnormality	8	6	2	0.41a
Antral gastritis	20	11	9	0.16a
Fundic exudative gastritis	6	4	2	0.65a
Atrophic gastritis	4	3	1	0.56a
Ulcerative Nodular antral disease	2	2	0	0.41a
Grade of duodenal nodular disease (Number of patients)
Grade 1	4	2	2	0.71b
Grade 2	10	7	3
Grade 3	20	14	6
Grade 4	6	3	3
Mean ± 1SD Score	2.70 ± 0.84	2.69 ± 0.79	2.71 ± 0.96	0.94c
Follow up months (mean ± 1SD)	24 ± 12.5 (6-56)	22 ± 14.5 (6-54)	26 ± 12.9 (8-56)	0.65c

a = Fisher's exact test 2 × 2 table; b = Fisher's exact test rxc table; c = students t test.
Key: The profile of 26 patients in whom H. pylori infection was eradicated and 14 patients in whom H. pylori infection was resistant to eradication therapy are compared.

ISSN: 1471-230X